
Penumbra (PEN) Stock Forecast & Price Target
Penumbra (PEN) Analyst Ratings
Bulls say
Penumbra Inc demonstrated significant growth in December, achieving its highest monthly volume of VTE procedures ever, with overall thrombectomy sales increasing by 16.9% and total sales for embolization and aspiration (E&A) rising by 5.1%. The company reported a year-over-year improvement in non-GAAP operating margin, which increased by 200 basis points, driven by enhanced gross margins and reduced research and development expenses, culminating in an operating margin of 15.1%. Additionally, the gross margin rose by 170 basis points to 67.4%, indicating strong product mix benefits and improved operational productivity.
Bears say
Penumbra Inc faces a challenging outlook, with projected revenue growth anticipated to decline to less than 12% due to lower-than-expected contributions from new products and a lag in profitability improvements. Recent revenue estimates for 2025 and 2026 have been lowered to $1.349 billion and $1.531 billion, respectively, reflecting concerns over market share loss to competitors and persistent risks related to product launches and supply chain disruptions. Additionally, pressures in the international market, particularly in China, further exacerbate the company's financial challenges.
This aggregate rating is based on analysts' research of Penumbra and is not a guaranteed prediction by Public.com or investment advice.
Penumbra (PEN) Analyst Forecast & Price Prediction
Start investing in Penumbra (PEN)
Order type
Buy in
Order amount
Est. shares
0 shares